Global COVID-19 Diagnostic Demand Outlook Report 2021 with Focus on Molecular and Serology Testing
Dublin, Aug. 26, 2021 (GLOBE NEWSWIRE) -- The "COVID-19 Global Diagnostic Demand Outlook Report" report has been added to ResearchAndMarkets.com's offering.
Can diagnostics stop an epidemic? Rapid diagnostics are key to epidemic management, but the demand is staggering. Will it stagger the diagnostics industry?
This report looks at the assay volume demands by country looking out 5 quarters to the end of 2021. The publisher looks at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario. A breakout of Molecular and Serology is also included.
The forecasts are based on the WHO Health Security Index with specific assumptions about the effectiveness of distancing measures and the impact of health system overload on different countries. These create varying timelines of demand.
Key Topics Covered:
COVID-19. Strategic Situation Analysis
COVID-19. Guidance for Executives
COVID-19. Guidance for Management Consultants and Investment Advisors
1. Introduction and Market Definition
1.1 What are Pandemics?
1.2 The Role of Zoonosis
1.3 Market Definition
1.3.1 Assay Volumes.
1.3.2 Healthcare Systems Demand
1.3.3 Molecular & Serology
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 Historical Perspective on Pandemics
2. The Pandemic Overview
2.1 What is a Virus?
2.1.1 Is a Virus Alive?
2.1.2 Viral Structure
2.1.3 The Viral Genome
2.1.4 Viral Mutation
2.2 The Coronavirus
2.2.1 Severe acute respiratory syndrome (SARS)
2.2.2 Middle East respiratory syndrome (MERS)
2.2.3 COVID-19. The SARS CoV 2 Virus.
2.2.3.1 Signs and symptoms
2.2.3.2 Transmission
2.2.3.3 Diagnosis
2.2.3.4 Prevention
2.2.3.5 Management
2.2.3.6 Prognosis
2.2.3.7 A Note on Global Statistics Reporting
2.3 Pandemic Diagnostics
2.3.1 Risk Management - Spark and Spread
2.3.2 Dx Technology - Nucleic Acid Based
2.3.3 Dx Technology - Immunoassay
2.3.4 Time to Market and Preparedness Issues
2.3.5 Saliva Direct Test
2.3.5.1 Research Abstract
2.3.5.2 FDA Statement on Saliva Direct Test
2.3.5.3 Impact of Saliva Direct on Forecasts and Cannibalization
3. Infection/Hospitalization Projections by Country by Quarter. All Case Scenarios
3.1 Scenarios Overview
3.1.1 WHO Global Health Security Index
3.1.2 Pandemic Progression Outlook Methodology
3.2 Scenario 1. Best Case
3.3 Scenario 2. Expected Case
3.4 Scenario 3. Worst Case
4. Diagnostic Company Profiles
1drop
Abbott Diagnostics
Accelerate Diagnostics
Ador Diagnostics
Advanced Biological Laboratories
Akkoni Biosystems
Altona Diagnostics
Alveo Technologies
Applied BioCode
Applied DNA Sciences
Anatolia Geneworks
Assurance Scientific Laboratories
Aus Diagnostics
Autobio Diagnostics
BD Diagnostics
BGI Genomics Co. Ltd
Biocartis
Biodesix
BioFire Diagnostics
Biolidics
bioMerieux
Bioneer
Bio-Rad Laboratories
BioReference Laboratories
Bosch Healthcare Solutions GmbH
Cepheid
Cerstest Biotec
Chembio Diagnostics
Color Genomics
Credo Diagnostics Biomedical
Curetis
Diagenode Diagnostics
Diascopic
Diasorin
Enzo Life Sciences, Inc.
Exact Sciences
Expedeon
Fulgent Genetics
Fusion Genomics.
Genedrive
GenePOC Diagnostics
Genetic Signatures
Genetron
GenMark Dx
Gold Standard Diagnostics
Hologic
Immunexpress
Inflammatix
Invetech
Janssen Diagnostics
Karius
Laboratory Corporation of America
Lexagene
Luminex
Mayo Clinic Laboratories
Mbio Diagnostics
Meridian Bioscience
Mesa Biotech
Mobidiag
Nanomix
Novacyt
Orig3n
Ortho Clinical Diagnostics
Oxford Nanopore
Panagene
PerkinElmer
Primerdesign
Prominex
Qiagen (Statdx)
Quantumdx
Quest Diagnostics
Quidel
Randox Laboratories
Roche Molecular Diagnostics
Saw Diagnostics
SD Biosensor
Seegene
Sensovation
Siemens Healthineers (Fast Track Diagnostics)
SkylineDx
Sona Nanotech
T2 Biosystems
Thermo Fisher
Veredus Labs
Vircell
YD Diagnostics
Zhejiang Orient Gene Biotech
5. Healthcare Systems Dx Demand Outlook
5.1 Healthcare System Demand by Country - Best Case
5.2 Healthcare System Demand by Country - Expected Case
5.3 Healthcare System Demand by Country - Worst Case
6. Molecular/Serology Dx Demand Outlook
6.1 Molecular/Serology Demand by Country - Best Case
6.2 Molecular/Serology Demand by Country - Expected Case
6.3 Molecular/Serology Demand by Country - Worst Case
For more information about this report visit https://www.researchandmarkets.com/r/ua10r2
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900